Cargando…

Leukocyte–endothelial interaction in CKD

Chronic kidney disease (CKD) represents an independent risk factor for cardiovascular diseases (CVD). Accordingly, CKD patients show a substantial increased risk of cardiovascular mortality. Inflammation represents an important link between CKD and CVD. The interaction between endothelial cells and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarakpi, Tamim, Mesic, Armir, Speer, Thimoteus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	CKJ Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616504/ https://www.ncbi.nlm.nih.gov/pubmed/37915921 http://dx.doi.org/10.1093/ckj/sfad135

Ejemplares similares

Thiazide diuretics are back in CKD: the case of chlorthalidone
por: Minutolo, Roberto, et al.
Publicado: (2022)

Uric acid lowering for slowing CKD progression after the CKD-FIX trial: a solved question or still a dilemma?
por: Leoncini, Giovanna, et al.
Publicado: (2022)

Management of fracture risk in CKD—traditional and novel approaches
por: Haarhaus, Mathias, et al.
Publicado: (2022)

The effect of a ketogenic diet on weight loss in CKD: a randomized controlled trial in obese stage G1–3a CKD patients
por: Zoccali, Carmine, et al.
Publicado: (2023)

The emerging role of iron in heart failure and vascular calcification in CKD
por: Ciceri, Paola, et al.
Publicado: (2020)

Can we reverse arterial stiffness by intervening on CKD-MBD biomarkers?
por: Vervloet, Marc G
Publicado: (2023)

Plant-based diets for CKD patients: fascinating, trendy, but feasible? A green nephrology perspective
por: Torreggiani, Massimo, et al.
Publicado: (2022)

The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors
por: Locatelli, Francesco, et al.
Publicado: (2023)

Unmet needs in clinical trials in CKD: questions we have not answered and answers we have not questioned
por: Levin, Adeera, et al.
Publicado: (2022)

Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients
por: Hafez, Gaye, et al.
Publicado: (2023)

Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy
por: Shye, Michael, et al.
Publicado: (2020)

Citation classics: ranking of the top 100 most cited articles in nephrology
por: Montinaro, Vincenzo, et al.
Publicado: (2018)

The new Clinical Kidney Journal, 4 years later
por: Ortiz, Alberto, et al.
Publicado: (2019)

Immune checkpoint inhibitors and their interaction with proton pump inhibitors–related interstitial nephritis
por: Miao, Jing, et al.
Publicado: (2023)

Kidney and blood pressure regulation—latest evidence for molecular mechanisms
por: Suzumoto, Yoko, et al.
Publicado: (2023)

Asymptomatic hyperuricaemia in chronic kidney disease: mechanisms and clinical implications
por: Anders, Hans-Joachim, et al.
Publicado: (2023)

Immunotherapy in oncology and the kidneys: a clinical review of the evaluation and management of kidney immune-related adverse events
por: Rao Ullur, Avinash, et al.
Publicado: (2023)

Challenges of defining renal response in ANCA-associated vasculitis: call to action?
por: Odler, Balazs, et al.
Publicado: (2023)

Interventions to support decision-making, health literacy and self-management in ethnic-minority adults living with chronic kidney disease: a systematic review
por: Kanagaratnam, Roshana, et al.
Publicado: (2023)

Deprivation and chronic kidney disease—a review of the evidence
por: Grant, Christopher H, et al.
Publicado: (2023)

Immune abnormalities in IgA nephropathy
por: Gentile, Micaela, et al.
Publicado: (2023)

Expanded hemodialysis: what’s up, Doc?
por: García-Prieto, Ana, et al.
Publicado: (2023)

War in Ukraine and dialysis treatment: human suffering and organizational challenges
por: Novakivskyy, Volodymyr, et al.
Publicado: (2023)

A new immune disease: systemic hypertension
por: Copur, Sidar, et al.
Publicado: (2023)

New and old GFR equations: a European perspective
por: Delanaye, Pierre, et al.
Publicado: (2023)

Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN)
por: Rojas-Rivera, Jorge E, et al.
Publicado: (2023)

Kidney function changes in acute heart failure: a practical approach to interpretation and management
por: Kenneally, Laura Fuertes, et al.
Publicado: (2023)

Chronic kidney disease in children: an update
por: Cirillo, Luigi, et al.
Publicado: (2023)

Pharmacokinetic relevance of glomerular hyperfiltration for drug dosing
por: Zoccali, Carmine, et al.
Publicado: (2023)

Is there a role in acute kidney injury for FGF23 and Klotho?
por: Mattinzoli, Deborah, et al.
Publicado: (2023)

A learning process to deliver virtual staff training involving patients in shared haemodialysis care
por: Barnes, Tania, et al.
Publicado: (2023)

Shared decision making: a personal view from two kidney doctors and a patient
por: Hole, Barnaby, et al.
Publicado: (2023)

The role of low health literacy in shared treatment decision-making in patients with kidney failure
por: Toapanta, Néstor, et al.
Publicado: (2023)

An update on absolute and relative indications for dialysis treatment modalities
por: Lambie, Mark, et al.
Publicado: (2023)

Partnering with patients and caregivers to enrich research and care in kidney disease: values and strategies
por: Cazzolli, Rosanna, et al.
Publicado: (2023)

Decision aids to assist patients and professionals in choosing the right treatment for kidney failure
por: Bekker, Hilary L, et al.
Publicado: (2023)

From electronic health records to clinical management systems: how the digital transformation can support healthcare services
por: Barbieri, Carlo, et al.
Publicado: (2023)

What is central to renal nutrition: protein or sodium intake?
por: Wang, Angela Yee-Moon, et al.
Publicado: (2023)

Management of traditional risk factors for the development and progression of chronic kidney disease
por: Lo, Robin, et al.
Publicado: (2023)

Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)
por: Sarafidis, Pantelis, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t5k9l1nf3c4eqm8o2mslavibk1